Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
S CulineGenito-Urinary Group of the French Federation of Cancer Centers Trial T93MP

Abstract

Two chemotherapy regimens for intermediate- and poor-risk metastatic nonseminomatous germ cell tumors were compared for efficacy and toxicity. From February 1994 to February 2000, 190 patients were randomly assigned between either four cycles of BEP (bleomycin 30 mg d1, d8, d15; etoposide 100 mg/m(2) d1-5; cisplatin 20 mg/m(2) d1-5) or four to six alternating cycles of CISCA/VB (cyclophosphamide 400 mg/m(2) d1-2, doxorubicin 35 mg/m(2) d1-2, cisplatin 100 mg/m(2) d3/vinblastine 2.5 mg/m(2) d1-5, bleomycin 25 mg/m(2) d1-5). Risk was initially defined according to the Institut Gustave Roussy (Villejuif, France) prognostic model based on serum alpha-fetoprotein and human chorionic gonadotropin levels only. Patients were retrospectively assigned into the International Germ Cell Consensus Classification. Among 185 assessable patients, favorable responses did not differ statistically between the two arms: 49 in the CISCA/VB arm (56%; 95% CI, 45% to 66%), 57 in the BEP arm (65%; 95% CI, 55% to 75%). The CISCA/VB regimen induced more significant hematologic and mucous toxicities compared with the BEP arm. The 5-year event-free survival rates were 37% (95% CI, 27% to 47%) and 47% (95% CI, 37% to 57%) in CISCA/VB and BEP arms, respective...Continue Reading

References

Nov 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L H Einhorn
Jul 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C R NicholsL H Einhorn
Jun 4, 1987·The New England Journal of Medicine·S D WilliamsP J Loehrer
Mar 1, 1985·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C J LogothetisA C von Eschenbach
Jan 1, 1981·Cancer·A B MillerA Winkler
Jan 1, 1993·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J P DrozJ L Pico
Jul 24, 1997·The New England Journal of Medicine·G J Bosl, R J Motzer
Jan 1, 1997·Clinical Oncology : a Journal of the Royal College of Radiologists·G M Mead, S P Stenning
Aug 11, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Karim FizaziChristopher J Logothetis
Aug 21, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H J SchmollUNKNOWN European Germ Cell Cancer Consensus Group

❮ Previous
Next ❯

Citations

Mar 3, 2009·Der Urologe. Ausg. A·A HeidenreichR Souchon
Mar 31, 2009·World Journal of Urology·Matthew J Riese, David J Vaughn
Apr 9, 2013·Apoptosis : an International Journal on Programmed Cell Death·Denis SelimovicMohamed Hassan
Jun 19, 2012·Current Oncology Reports·Alison J Moskowitz
Apr 14, 2009·Current Opinion in Oncology·Heather D Mannuel, Arif Hussain
Sep 23, 2010·AJR. American Journal of Roentgenology·Atul B ShinagareAnnick D Van den Abbeele
Dec 21, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P S GrimisonUNKNOWN Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Jun 26, 2013·BJU International·Mariam Jamal-HanjaniSimon Chowdhury
Feb 6, 2015·International Journal of Clinical Oncology·Naotaka NishiyamaNaoya Masumori
May 17, 2011·Hematology/oncology Clinics of North America·Craig Nichols, Christian Kollmannsberger
Feb 16, 2019·Pediatric Blood & Cancer·Mohammad H Abu ArjaMohamed S AbdelBaki
Oct 21, 2009·BJU International·Gedske Daugaard
Dec 1, 2010·Nature Reviews. Endocrinology·Christian Winter, Peter Albers
Apr 13, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sven-Erik OlofssonEva Cavallin-Ståhl
Feb 22, 2017·Current Oncology Reports·J Clayton AllenAlicia K Morgans
Oct 7, 2018·Nature Reviews. Disease Primers·Liang ChengLeendert H J Looijenga
Oct 28, 2016·The Journal of Obstetrics and Gynaecology Research·Makiko HinoHiroyuki Nakagawa
Oct 27, 2015·American Journal of Physiology. Lung Cellular and Molecular Physiology·Biji MathewJeffrey R Jacobson
Feb 3, 2020·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Fay H CaffertyUNKNOWN TE23 Trial Management Group and Collaborators
May 13, 2021·Journal of Pediatric Surgery·Jennifer H AldrinkPeter F Ehrlich
Jun 3, 2021·Cancers·Mariana Tomazini PintoLuiz Fernando Lopes

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.